StonvexLoading…
StonvexCore line items from PSO's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | £3.58B | £3.55B | £3.67B | £3.84B |
Operating Income | £507.00M | £541.00M | £498.00M | £271.00M |
Net Income | £336.00M | £435.00M | £380.00M | £244.00M |
EPS (Diluted) | £0.51 | £0.64 | £0.53 | £0.33 |
Total Assets | £6.46B | £6.89B | £6.73B | £7.32B |
Total Liabilities | £2.79B | £2.84B | £2.74B | £2.91B |
Cash & Equivalents | £333.00M | £543.00M | £312.00M | £558.00M |
Free Cash Flow OCF − CapEx | Not available | Not available | Not available | Not available |
Shares Outstanding | 635.82M | 666.26M | 697.30M | 715.73M |